Schleich F, Louis R
Service de Pneumologie, CHU de Liège, Belgique.
Rev Med Liege. 2012;67 Spec No:14-21.
Asthma is a chronic inflammatory disease of the airways. The inflammatory process is driven by different pathways involving cytokines and other protein mediators. Patients with severe asthma are at high risk of severe exacerbations and death and have few therapeutic options available. Therefore, biological agents have been developed to help patients with refractory asthma by interfering with several compounds of the asthma inflammatory cascade. In addition to decreasing exacerbations, some of those treatments have a steroid sparing role and many beneficial effects in asthmatics.
哮喘是一种气道慢性炎症性疾病。炎症过程由涉及细胞因子和其他蛋白质介质的不同途径驱动。重度哮喘患者有发生严重急性加重和死亡的高风险，且可用的治疗选择很少。因此，已经开发出生物制剂，通过干扰哮喘炎症级联反应的几种化合物来帮助难治性哮喘患者。除了减少急性加重外，其中一些治疗方法还具有节省类固醇的作用，并对哮喘患者有许多有益影响。
